Patent SG-11201903771X-A (SG)
Title: Binding molecules specific for asct2 and uses thereof
Inventor: PORE NABENDU
IPC: A61K39/395
Filed: 2017-11-08
Abstract: MMBM W O 18/089393 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 17 May 2018 (17.05.2018) WIPOI PCT IiiimmomiolollmonoloolunionionovoimIE (10) International Publication Number WO 2018/089393 Al (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/30 (2006.01) A61K 47/68 (2017.01) G01N 33/574 (2006.01) C07K 16/18 (2006.01) (21) International Application Number: PCT/US2017/060489 (22) International Filing Date: 08 November 2017 (08.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/420,008 10 November 2016 (10.11.2016) US 62/501,923 05 May 2017 (05.05.2017) US (71) Applicant: MEDIMMUNE, LLC [US/US]; One Medlm- mune Way, Gaithersburg, MD 20878 (US). (72) Inventors: PORE, Nabendu; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). BOR- ROK III, Martin, J.; c/o Medlmmune, LLC, One Medlm- mune Way, Gaithersburg, MD 20878 (US). CHOWD- HURY, Partha, S.; c/o Medlmmune, LLC, One Medlm- mune Way, Gaithersburg, MD 20878 (US). MICHELOT- TI, Emil, F.; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). TICE, David, A.; c/o Medlmmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). HOLLINGSWORTH, Robert, E.; c/o Medlmmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). CHANG, Chien-Ying; c/o MedImmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). HURT, Elaine, M.; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). YAO, Nai, Shun; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). (74) Agent: GALVEZ, J., Jason et al.; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: BINDING MOLECULES SPECIFIC FOR ASCT2 AND USES THEREOF FIG. 1A 4000- =I Normal BM L T_ m 3000- AML BM MM BM E 2000- 1000- 0 , Normal BM AML BM (57) : This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments there- of, used in methods related to cancer stem cells, e.g., binding to a cancer stem cell. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates. In certain aspects, the ASCT2-binding molecules bind specifi- cally to cancer stem cells expressing ASCT2. [Continued on next page] WO 2018/089393 Al MIDEDIMOMOIDEIREIDIONIMEITHEMOVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))